Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2017

Sanmartín Elena, Muñoz Lisandra, Piqueras Marta, Sirerol J Antoni, Berlanga Pablo, Cañete Adela, Castel Victoria, Font de Mora Jaime

Abstract excerpt

Purpose: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20%-30%) undergo consecutive recurrences with poor outcome. We hypothesized that patients with 11q-loss may share a druggable molecular target(s) that can be exploited for a precision medicine strategy to improve treatment outcome.Experimental Design: SNP arrays were combined with next-generation sequencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Chromosomes, Human, Pair 11

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Immunophenotyping

Share to Kaplan-Meier Estimate

Share to Neuroblastoma

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28830922
DOI: 10.1158/1078-0432.CCR-17-0593

Genes

ATM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.PMID 28830922Read ↗

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitorsSemantic proximity Read ↗

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroupSemantic proximity Read ↗

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.Semantic proximity Read ↗

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaSemantic proximity Read ↗

Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case ReportSemantic proximity Read ↗

Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.Semantic proximity Read ↗

Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.Semantic proximity Read ↗

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsSemantic proximity Read ↗

Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.Semantic proximity Read ↗

Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.Semantic proximity Read ↗

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSemantic proximity Read ↗

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.